Infinita Expert

Stephen Martin. Expert Consultation.

Patient Access & Right-to-Try Strategy for Experimental Treatments.
Work directly with Stephen Martin to evaluate patient access opportunities through emerging state-level clinical pathways.

Together, you'll develop a submission strategy, and prepare your treatment for independent review under applicable frameworks.
Book 30-MinuteBook 30-Minute
Designed for biotechs preparing experimental treatment submissions.
DISCLAIMER: Independent scientific guidance. Consultations do not influence the outcome of any independent review process.
EXPERT PROFILE

Operational Leadership.

Stephen Martin leads U.S. initiatives at Infinita focused on expanding responsible patient access to experimental treatments through emerging state-level frameworks.

His work centers on translating legislation into practical clinical pathways by working closely with biotechnology companies, policymakers, clinicians, and independent review organizations.

Stephen has played a central role in the development and implementation of Montana's Experimental Treatment Review Board and has worked directly with treatment developers preparing therapies for clinical access under SB 535.
His experience spans pathway implementation, submission strategy, operational compliance, and patient access policy, helping biotechnology teams navigate new opportunities beyond conventional development models.

Professional Highlights.

U.S. Lead:
Infinita
Operations Lead:
Montana Experimental Treatment Review Board (METRB)
Speaker:
Right-to-Try & Patient Access Policy
Co-Founder:
GenePool Technologies

Affiliations.

Learn More.

Explore Stephen Martin's background.

Montana ETRB ↗

GenePool ↗

LinkedIn ↗

X (Twitter) ↗ .
Infinita
Bridging the Gap from
Biotech to Clinic.
Terms of Service.
‍Privacy Policy.
Compliance Center.
Design by Apofenia.
© 2026 Infinita City Inc.
251 Little Falls Drive,
Wilmington, DE 19808.
Infinita symbol grid